## Accumulator Adjustment Program State Model Language

#### Section 1. Legislative Purpose

(A) The legislature finds that cost sharing assistance is indispensable to help many patients with rare, serious, and chronic diseases afford out-of-pocket costs for their essential, often lifesaving, medications.

(B) The legislature further finds that patients need cost sharing assistance because of the high out-of-pocket cost of medications.

(C) The legislature further finds that when patients face unexpected charges during the plan year, they are less likely to adhere to their medication regimen.

(D) The legislature further finds that lack of patient adherence to needed medicines leads to potential negative health consequences for the patients, such as unnecessary emergency room visits, doctors' visits, surgeries, and other interventions.

(E) The legislature further finds that patients are only able to use cost sharing assistance after they have met requirement(s) for coverage of their medication. Requirements for coverage can include the medication's inclusion on the patient's formulary and utilization management protocols, such as prior authorization and step therapy.

(F) The legislature further finds that health insurers and pharmacy benefit managers (PBMs) have implemented programs, such as accumulator adjustment programs, to restrict cost sharing assistance from counting towards a patient's deductible or annual out-of-pocket limit.

(G) The legislature further finds that as a result of an accumulator adjustment program, a patient is required to continue to make payments even if the patient has already hit an out-of-pocket limit when including cost sharing assistance. As such, the cost sharing assistance depletes leaving the patient responsible for paying the full deductible and meeting the annual out-of-pocket limit for a second time. This means accumulator adjustment programs limit the benefit patients receive from copay assistance programs.

(H) The legislature further finds that patients often are not aware of the inclusion of accumulator adjustment programs in their health plan contracts. Patients tend to learn about these types of programs when they attempt to obtain their medication after their cost sharing assistance has run out, whether at the pharmacy, infusion center, or at home through the mail.

(I) The legislature further finds that accumulator adjustment programs allow health insurers and PBMs to "double dip" by accepting funds from both the cost sharing assistance program and the patient beyond the original deductible amount and the annual out-of-pocket limit.

(J) Therefore, the legislature declares it a matter of public interest that health insurers and PBMs must count any amount paid by the patient or on behalf of the patient by another person towards a patient's annual out-of-pocket limit and any cost sharing requirement, such as deductibles.

### Section 2. Definitions

(A) "Cost sharing" means any copayment, coinsurance, deductible, or annual limitation on cost sharing (including but not limited to a limitation subject to 42 U.S.C. §§ 18022(c) and 300gg-6(b)), required by or on behalf of an enrollee in order to receive a specific health care service, including a prescription drug, covered by a health plan, whether covered under the medical or pharmacy benefit.

(B) "Carrier" OR "Insurer" OR "Issuer" means [cross-reference state insurance statutes and use their existing definitions], and shall include, but not be limited to any health insurance company, nonprofit hospital and medical service corporation, managed care organization, and, to the extent permitted under federal law, any administrator of an insured, self-insured, or publicly funded health benefit plan offered by public and private entities. For the purposes of this section, "insurer" does not include self-insured employer plans governed by the Employee Retirement Income Security Act of 1974 (ERISA) (Pub.L. 93–406, 88 Stat. 829, as amended).

(C) "Health Plan" means a policy, contract, certificate, or subscriber agreement entered into, offered, or issued by a health insurance issuer to provide, deliver, arrange for, pay for, or reimburse any of the costs of healthcare services.

(D) "Person" means a natural person, corporation, mutual company, unincorporated association, partnership, joint venture, limited liability company, trust, estate, foundation, nonprofit corporation, unincorporated organization, or government or governmental subdivision or agency.

(E) "Pharmacy Benefit Manager" means any person or business who administers the prescription drug or device program of one or more health plans on behalf of a third party in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a pharmacy benefit manager.

<u>Drafting Note</u>: Use existing statutory definitions of "health plan" and "pharmacy benefit manager" when possible.

<u>Drafting Note:</u> If "person" is already in the state's definition, that includes corporation. Otherwise, can remove "by another person."

#### Section 3.

(A) When calculating an enrollee's overall contribution to any out-of-pocket maximum or any costsharing requirement under a health plan, a [CARRIER/INSURER/ISSUER] or pharmacy benefit manager shall include any amounts paid by the enrollee or paid on behalf of the enrollee by another person.

#### Section 4. Enactment

(A) This section shall apply with respect to health plans that are entered into, amended, extended, or renewed on or after January 1, 202##.

Organizations Endorsing Model Language

- Allergy & Asthma Network
- Alliance for Patient Access
- American Autoimmune Related Disease Association
- American Cancer Society Cancer Action Network
- American Kidney Fund
- American Medical Association
- Arthritis Foundation
- California Chronic Care Coalition
- Cancer Support Community
- Chronic Care Policy Alliance
- Coalition of State Rheumatology Organizations (CSRO)
- Cystic Fibrosis Research Inc.
- Diabetes Leadership Council
- **Diabetes Patient Advocacy Coalition**
- **Epilepsy Foundation**
- Gaucher Community Alliance
- Hemophilia Federation of America
- HIV + Hepatitis Policy Institute
- Infusion Access Foundation (IAF)
- Immune Deficiency Foundation
- International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis)
- Little Hercules Foundation
- Lupus and Allied Diseases Association, Inc.
- Multiple Sclerosis Association of America
- National Eczema Association
- National Hemophilia Foundation
- National Infusion Center Association (NICA)
- National Multiple Sclerosis Society
- National Psoriasis Foundation
- Pulmonary Hypertension Association
- Spondylitis Association of America
- Texas Rare Alliance
- The AIDS Institute

### <u>Contact</u>

For questions or concerns about this model language, please do not hesitate to reach out to co-chairs of the All Copays Count Coalition's state subgroup, Lindsay Gill at the American Kidney Fund at <u>lgill@kidenyfund.org</u> and Steven Schultz of the Arthritis Foundation at <u>sschultz@arthritis.org</u>.